AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04539483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Completion of questionnaires (patient-reported outcomes)
Description: Patients will be asked to document their health status in questionnaires by using their smart phone
Study NCT04539483 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Completion of questionnaires (patient-reported outcomes)
Description: Patients will be asked to document their health status in questionnaires by using their smart phone
Study NCT04539483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 28-day swabbing of orolabial region
Description: Patients will be asked to complete 3 episodes of 28-day swabbing of orolabial lesions
Study NCT04539483 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 28-day swabbing of orolabial region
Description: Patients will be asked to complete 3 episodes of 28-day swabbing of orolabial lesions
Study NCT04539483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood drawings
Description: Blood will be drawn for e.g. safety lab, HSV-analysis, pharmacokinetic etc.
Study NCT04539483 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood drawings
Description: Blood will be drawn for e.g. safety lab, HSV-analysis, pharmacokinetic etc.
Study NCT03752086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: greater omentum binding
Description: Bind pancreatic stump using greater omentum after distal pancreatectomy
Study NCT03752086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatic stump exposed without omentum binding
Description: Pancreatic stump exposed without greater omentum binding after distal pancreatectomy
Study NCT04028323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Terlipressin should be administrated intravenously while monitoring heart rate and blood pressure daily.
Study NCT04028323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Octreotide should be continuously intravenously administrated while monitoring heart rate and blood pressure daily.
Study NCT02290119 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensor-assisted TKR (Verasense)
Description: Verasense is a single use, disposable device embedded with microelectronics into a standard tibial trial to provide dynamic, intraoperative feedback regarding limb alignment, tibiofemoral position and quantitative pressure at peak contact points in the medial and lateral compartments during total knee replacement surgery. Utilizing sensor-derived data, the surgeon can now evaluate intercompartmental loading throughout the range of motion, and correct for soft-tissue abnormalities while receiving real-time feedback regarding joint balance.
Study NCT02290119 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control - Without the use of Verasense
Description: Patients in this cohort will undergo manual total knee replacement without the use of Verasense
Study NCT00985933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8529
Description: 6 capsules by mouth 1 time 12 to 24 prior to assessments
Study NCT00985933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD8529
Description: 6 capsules by mouth 1 time 12 to 24 prior to assessments
Study NCT00985933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match AZD8529
Description: 6 capsules by mouth 1 time 12 to 24 hours prior to assessments
Study NCT00985933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match AZD8529
Description: 6 capsules by mouth 1 time 12 to 24 hours prior to assessments
Study NCT03699371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Supplemental Parenteral Nutrition
Description: Intervention group: would receive EN reaching up to 20 % of daily nutritional requirements and early (on first day of stay in ICU) provision (of up to 80%) of protein (2 g/kg/ day or in case of CRRT 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day) needs in SPN that would be continued until 7th day of stay in ICU. Central venous catheter placement would not be assessed as a part of intervention due to the fact that it is a part of routine medical activities performed during admission to ICU.
Study NCT04039425 — intervention group
Intervention type: PROCEDURE
Intervention: Hair cut
Description: Use only head hair. Cut samples of hair from back of head (see illustration). Cut hair as close to the scalp as possible. As each piece of hair is cut from the head, save only 3.7 square inches of hair closest to the scalp. According to the Doctors Data Lab, this amount is about enough hair to fill a tablespoon. Cut off and discard the rest. Place the saved hair on the scale. Keep cutting and adding hair to the scale until it tips. Hair collection will be about the weight of one to two paper clips (about 3800 strands). Remove the hair on the scale and put it in the plastic bag. Label the plastic bag with the patient's unique random identification and the date collected. Put the hair into the plastic bag, seal, and send to The Doctor's Data Lab.
Study NCT00857467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001
Description: Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 1 g rectal suppository, with a 7-day washout period between dosing.
Study NCT00857467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001
Description: Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository, with a 7-day washout period between dosing.
Study NCT03309228 — intervention group
Intervention type: OTHER
Intervention: individual interviews
Description: Semi-structured individual interviews with patients, relatives and general practitioners.
Study NCT01786031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: metastasis biopsy
Study NCT01773018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volitinib
Description: Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mgand 200 mg,oral,once daily.
Study NCT06124651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement with cruciate retaining femoral component
Description: To perform the total knee replacement, the knee joint is anatomically dissected, and thin portions of bone and cartilage is resected to accommodate a metallic implants. Implants are fixed to patients' bone with bone cements. Many designs for femoral component designs are available. In the present study, two types of implants, one CR(cruciate retaining), where the posterior cruciate ligaments are retained, and one PS(Posterior cruciate substituting), where the posterior cruciate ligaments are resected, will be compared. To make the comparison more reliable, the same kind of implants will be used, so that the major portions of femoral component design remains the same and the tibial component remains the same. Only the cruciate ligament parts are different. For this arm of intervention, CR knee will be used, so posterior cruciate will remain intact after the surgery and still function to aid in the knee stability.
Study NCT06124651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement with cruciate substituting femoral component
Description: To perform the total knee replacement, the knee joint is anatomically dissected, and thin portions of bone and cartilage is resected to accommodate metallic implants that has similar contours of a native knee. Implants are fixed to patients' bone with bone cements. This procedure will use the femoral component that sacrifice the posterior cruciate ligament and having a box area with a post, so that cam-post mechanism of implants can mimic the function of the posterior cruciate ligament. To make the comparison more reliable, the same kind of implants will be used, so that the major portions of femoral component remains the same. The tibial component will remain the same design. Therefore, only the cruciate ligament parts will be different.
Study NCT04330222 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 7 Tesla Magnetic Resonance Imaging
Description: Diagnostic Imaging
Study NCT04330222 — intervention group
Intervention type: OTHER
Intervention: Brief Memory and Executive Test
Description: Cognitive Assessment
Study NCT00619372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKT3
Description: 0.2 mg OKT3, PO (in the mouth) on day 1 through 5.
Study NCT00619372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKT3, GC
Description: 0.2 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
Study NCT00619372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKT3
Description: 1 mg OKT3, PO (in the mouth) on day 1 through 5
Study NCT00619372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKT3, GC
Description: 1 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
Study NCT00619372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKT3
Description: 5 mg OKT3, PO (in the mouth) on day 1 through 5
Study NCT00619372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC
Description: 7.5 mg GC, PO (in the mouth) on day 1 through 5
Study NCT02474134 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Interferon beta-1b (PF530, Betaferon)
Description: Single subcutaneous administration
Study NCT02711020 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Patients assigned to this arm will receive a maximum of 18 1-hour sessions of Cognitive Behavioral Therapy following the intervention techniques included in various group therapy manuals for patients with fibromyalgia, plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. Techniques are adapted to individual format in the following modules: (1) Psychoeducation, (2) Relaxation, (3) Behavioral Activation, (4) Cognitive Restructuring, (5) Problem solving, (6) Assertiveness Training, and (7) Relapse Prevention.
Study NCT02711020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Construct Therapy
Description: Patients will receive a maximum of 18 1-hour sessions of Personal Constructs Therapy plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. The intervention will follow a protocol designed specifically for this project based on the clinical experience of a previous pilot study. It will consist of 4 stages: (1) Analysis of patient's request, goals setting, identification of the main dilemmas, and other personal meanings relevant for self and others' construction; (2) feedback on the assessment results and problem reframing in terms of a dilemma and/or other personal meanings; (3) work on the dilemmas and/or other aspects of the self and others' construction; and (4) end of the therapeutic process outlining personal projects and future perspectives.
Study NCT00660595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Oral administration
Study NCT00660595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Oral administration
Study NCT03594955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR440234
Description: Pharmaceutical form:lyophilisate to be resuspended in solution Route of administration: intravenous
Study NCT03302507 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BESS
Description: Biportal endoscopic surgery
Study NCT03302507 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ULBD
Description: Unilateral laminotomy bilateral decompression
Study NCT03580395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500mg, day1-21,neoadjuvant therapy
Study NCT03580395 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel 165mg/m2 day 1
Study NCT03580395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 165mg/m2 day 1
Study NCT04629456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromuscular electric stimulation
Description: A total of eight electrodes were placed on the quadriceps femoris muscles (four on each leg): two on the vastus medialis, one on the rectus femoris muscle, and one on the vastus lateralis muscle. The stimulation protocol of the NMES consisted of a symmetrical biphasic square pulse at 75 Hz, a duty cycle of 6 seconds (sec.) on and 29 sec. off, a pulse time of 410 sec. during a session lasting 20 min. The intensity was increased to maximum individual toleration. The muscle contractions were visible and palpable.
Study NCT04629456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: The chair-seated exercises were used in the early stages of the program because the participants were frail adults. Repetitions of toe raises, heel raises, knee lifts, knee extensions, and others were performed while seated on a chair. Hip flexions, lateral leg raises, and repetitions of other exercises were performed standing upright behind the chair and holding the back of the chair for stability. To strengthen lower extremities, a fixed weight was placed on the ankle while participants performed strengthening exercises. Weights of 0.50, 0.75, 1.00, and 1.50 kg were used in accordance with each participant's strength level as the resistance progressively increased. The exercises performed using these ankle weights included seated knee flexion and extension and standing knee flexion and extensions. Exercises using a resistance band: Resistance bands were used to strengthen lower body. Lower body exercises included leg extension and hip flexion
Study NCT03580395 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: cisplatin
Description: cisplatin 40mg, day 1-3
Study NCT03580395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin 40mg, day 1-3
Study NCT03049423 — intervention group
Intervention type: DEVICE
Intervention: MRI scans
Description: 30 patients with ankle ligament and tendon injury were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the trial group. Each participant was required to undergo MRI scans in normal position and during complete plantar flexion and complete dorsiflexion.
Study NCT03049423 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scans and general physical examination
Description: 30 patients with normal ankle joint were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the control group. Each participant was required to undergo MRI scans and general physical examination in normal position and during complete plantar flexion and complete dorsiflexion.
Study NCT02446535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: achievement of the DW by means of the BIA DW (RE.S.T.)
Study NCT01443923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boceprevir
Study NCT00615147 — intervention group
Intervention type: PROCEDURE
Intervention: CT pulmonary angiogram and d-dimer draw
Description: A CT pulmonary angiogram and a d-dimer drawn within 24 hours.
Study NCT04767971 — intervention group
Intervention type: DEVICE
Intervention: Standard Colonoscopy
Description: Colonoscopy with a standard colonoscope
Study NCT04767971 — intervention group
Intervention type: DEVICE
Intervention: G-EYE Colonoscopy
Description: Colonoscopy with a G-EYE Colonoscope
Study NCT01148459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biological's Investigational Malaria Vaccine 257049
Description: All infants enrolled to group A will receive 3 doses of the experimental vaccine. The vaccine will be administered intramuscularly.
Study NCT01148459 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);
Description: To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly
Study NCT01148459 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).
Description: To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly.
Study NCT03675971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabinol
Description: Postoperative pain treatment
Study NCT03675971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo comparator
Study NCT04565405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detergent
Description: The tracheostomy inner cannulas will be washed with detergent.
Study NCT04565405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile water
Description: The tracheostomy inner cannulas will be washed with sterile water.
Study NCT00402623 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: quercetin
Description: 1000 mg quercetin within 24 hours
Study NCT00402623 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02008032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stationary Breast Tomosynthesis
Description: The patient will have the SDBT study performed in a similar manner as conventional mammography in the mediolateral oblique and cranio-caudal plane. The participant will stand up and the mammography research technologist, ensuring patient comfort, will assist in positioning their breast in the breast tomosynthesis unit with standard compression. Once positioned, the total scan time is approximately 10 seconds. Both the left and right breast will be imaged. The length of time for the positioning and examination of a subject's breast may vary but it is expected that the entire imaging procedure will take about 5-10 min, including positioning time.
Study NCT02164071 — intervention group
Intervention type: OTHER
Intervention: Geriatric Assessment of Health Status Scale administration
Description: Scale will be administered to all patients (3 cohorts) at baseline and then after 5 and not more than 15 days
Study NCT04272047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee Control+ program
Description: 15-20 minute training program to be performed at all team training sessions during the season.
Study NCT04272047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adductor strengthening program
Description: Adductor strengthening program to be performed 2-3 times per week, one set per side, during the pre-season, and 1 time per week, one set per side during the in-season.
Study NCT04272047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knee Control program
Description: 15-20 minute training program to be performed as per the team's usual routines (no intervention from the researchers).
Study NCT03718234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous hydrocortisone
Description: Patients will be monitored and receive an interval bolus SQHC dosing regimen that more closely mimics cortisol, 17OHP and D4A circadian and ultradian rhythms than conventional oral HC dosing.
Study NCT03718234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard glucocorticoid therapy
Description: Subjects in this arm will continue on standard oral hydrocortisone therapy
Study NCT04184011 — intervention group
Intervention type: DEVICE
Intervention: SRT-100™
Description: SRT delivers a precise, calibrated dose of radiotherapy following surgical excision for large and more difficult-to-treat keloids that cannot otherwise be treated by or have failed more conservative measures.
Study NCT01491841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine + Rituximab + Pixantrone
Description: Dose escalation of pixantrone (55mg/m2, 85mg/m2 and 115mg/m2) in combination with static dose bendamustine (120mg/m2 on Day 1 of each 21 day) and rituximab (375mg/m2 on Day 1 of each 21 day cycle).
Study NCT01491841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6mg administered on Day 2 of each 21 day cycle
Study NCT01090050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan/Naproxen Sodium
Description: Each tablet of Sumatriptan/Naproxen Sodium for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
Study NCT01090050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium
Description: Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
Study NCT02871284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT02871284 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study NCT00845936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 850 mg bid
Study NCT00845936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin 850 mg bid
Study NCT03539484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7172508
Description: RO7172508 was administered at a dose and as per the schedule specified in the respective arms.